Stopping Denosumab.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_6E92DA5E8472
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Stopping Denosumab.
Journal
Current osteoporosis reports
Author(s)
Lamy O., Stoll D., Aubry-Rozier B., Rodriguez E.G.
ISSN
1544-2241 (Electronic)
ISSN-L
1544-1873
Publication state
Published
Issued date
02/2019
Peer-reviewed
Oui
Volume
17
Number
1
Pages
8-15
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.
In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple vertebral fractures is common or frequent (≥ 1/100 and < 1/10). In five recent case series, the median number of vertebral fractures was 5 within 7 to 20 months (median 11) after the last denosumab injection. Prescribing bisphosphonate before starting denosumab and/or after stopping denosumab may reduce this risk. However, only small case series have evaluated these strategies. After the second denosumab dose, there is a rebound effect with an increased risk of multiple vertebral fractures. A potent bisphosphonate prescribed at denosumab discontinuation could reduce this risk. As denosumab discontinuation is characterized by many uncertainties, denosumab is a second-line treatment for osteoporosis. Studies are urgently needed to define the management of denosumab discontinuation.
Keywords
Bone Density Conservation Agents/adverse effects, Bone Density Conservation Agents/therapeutic use, Denosumab/adverse effects, Denosumab/therapeutic use, Diphosphonates/therapeutic use, Humans, Osteoporosis, Postmenopausal/drug therapy, Risk Factors, Spinal Fractures/chemically induced, Spinal Fractures/prevention & control, Withholding Treatment, Denosumab discontinuation, Osteoporosis, Rebound effect, Spontaneous multiple vertebral fractures
Pubmed
Web of science
Create date
28/01/2019 9:09
Last modification date
05/04/2020 5:20
Usage data